Drug intelligence / Profile preview

methylphenidate + vitamin D

Development stage
Preclinical
Lead developer
Janssen Pharmaceutica
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Oral, Transdermal, Intramuscular
01

Overview

This is a combination therapy consisting of methylphenidate, a central nervous system stimulant primarily used to treat attention-deficit/hyperactivity disorder (ADHD), and vitamin D, a fat-soluble secosteroid involved in calcium homeostasis and bone metabolism. Methylphenidate acts as a norepinephrine–dopamine reuptake inhibitor, increasing the synaptic concentrations of these neurotransmitters in the brain to improve attention and reduce hyperactivity[5]. Vitamin D supplementation has been studied as an adjunctive therapy with methylphenidate for ADHD; evidence suggests it may provide additional improvement in ADHD symptoms, particularly evening symptoms, without significant adverse effects[1][3]. The combination is not available as a fixed-dose pharmaceutical product but refers to concurrent use of both agents.

02

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on methylphenidate + vitamin D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylphenidate + vitamin D.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call